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Long-term Graft Survival and Graft Function 
Following Pregnancy in Kidney Transplant 
Recipients: A Systematic Review and Meta-analysis
Marleen C. van Buren, MSc,1 Anouk Schellekens, MD,2 T. Katrien J. Groenhof, MD,3 Franka van Reekum, MD,4  
Jacqueline van de Wetering, MD, PhD,1 Nina D. Paauw, MD, PhD,2 and A. Titia Lely, MD, PhD2
INTRODUCTION
With increasing numbers of kidney transplantation (KT) 
performed worldwide and good short-term pregnancy as 
well as graft outcomes, there is an increasing incidence 
of pregnancy in KT patients. In 2011, over 11 000 births 
after KT have been reported worldwide.1 The Transplant 
Pregnancy Registry International (TPR) reported, in 2018, 
a total of 1993 pregnancies in 1101 KT recipients in the 
United States.2 Pregnancy in KT recipients is labeled as 
high risk with increased fetal and maternal risks for adverse 
pregnancy outcome. Reported live birth rates after KT are 
consistently between 72% and 80%.1,3,4 Compared to the 
US general population, pregnancies after KT are associ-
ated with higher rates of cesarean sections (56.9% versus 
31.9%), preterm (<37 wk of gestation), deliveries (45.6% 
versus 12.5%) and increased rates of small for gestational 
age and low birth weight (mean birth weight 2420 g ver-
sus 3298 g).1,4 In addition, the pregnancies are reported to 
have high maternal complication rates of hypertension and 
proteinuria5: with an increased risk to develop pre-eclamp-
sia 27% versus 3%. In previous meta-analysis, 4.2% of 
recipients experienced an episode of acute rejection during 
their pregnancy.1
Besides the pregnancy-related complications mentioned 
above, little is known on what effect pregnancy has on 
long-term graft survival and graft function. At the time of 
KT, the transplanted kidney develops compensatory renal 
hypertrophy, which results in hyperfiltration.6 During preg-
nancy, physiological changes occur in the kidney and cardi-
ovascular system, including vasodilatation and increase in 
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Original Clinical Science—General
Background. The incidence of pregnancy in kidney transplantation (KT) recipients is increasing. Studies report that the 
incidence of graft loss (GL) during pregnancy is low, but less data are available on long-term effects of pregnancy on the 
graft. Methods. Therefore, we performed a meta-analysis and systematic review on GL and graft function, measured by 
serum creatinine (SCr), after pregnancy in KT recipients, stratified in years postpartum. Furthermore, we included studies 
of nulliparous KT recipients. Results. Our search yielded 38 studies on GL and 18 studies on SCr. The pooled incidence 
of GL was 9.4% within 2 years after pregnancy, 9.2% within 2–5 years, 22.3% within 5–10 years, and 38.5% >10 years 
postpartum. In addition, our data show that, in case of graft survival, SCr remains stable over the years. Only within 2 years 
postpartum, ∆ SCr was marginally higher (0.18 mg/dL, 95%CI [0.05-0.32], P = 0.01). Furthermore, no differences in GL 
were observed in 10 studies comparing GL after pregnancy with nulliparous controls. Systematic review of the literature 
showed that mainly prepregnancy proteinuria, hypertension, and high SCr are risk factors for GL. Conclusions. Overall, 
these data show that pregnancy after KT has no effect on long-term graft survival and only a possible effect on graft func-
tion within 2 years postpartum. This might be due to publication bias. No significant differences were observed between 
pre- and postpartum SCr at longer follow-up intervals.
(Transplantation 2020;104: 1675–1685).
<zdoi;10.1097/TP.0000000000003026>
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glomerular filtration rate (GFR).7 This increased pressure 
and/or plasma flow during pregnancy on top of the already 
existing hyperfiltration may cause progressive loss of graft 
function due to glomerular sclerosis.6 It is unknown which 
effect this temporary extra demand has on the long-term 
graft survival and graft function. These insights would be 
helpful in preconceptional counseling of KT patients.
A meta-analysis of KT recipients published in 2011 ana-
lyzed graft loss (GL) incidence in a small number of ret-
rospective studies, reporting 8% postpregnancy GL at 2 
years, 7% at 5 years, and 19% at 10 years.1 Limited stud-
ies reviewed a year later showed no significant increase 
in serum creatinine (SCr) at 3 months and GL at 2 years 
postpartum.8 No reviews analyzed the effect on long-term 
consequence of pregnancy on graft function (SCr).
A limitation of previous meta-analysis and reviews is 
that they did not include a control group of nulliparous 
KT recipients.1,8 Furthermore, they do not systematically 
report on predictive factors regarding long-term graft 
function after pregnancy.
Currently, optimal timings of pregnancy after KT are 
described as follows: an interval of >1 year between KT 
and pregnancy, and an interval of >1 year between the last 
episode of acute rejection. Furthermore, SCr levels should 
be below 1.5 mg/dL, no acute infections should be pre-
sent, and stable maintenance of nonteratogenic immuno-
suppressive medication.9,10 However, the aforementioned 
guidelines are based mainly on data from voluntary reg-
istries and expert opinions, focusing primarily on (predic-
tors of) adverse pregnancy outcomes.
To increase insight in the effect of pregnancy on long-
term graft survival and function as guidance for preconcep-
tional counseling: the aim of this study was to perform an 
updated meta-analysis on graft survival with comparison 
with nonpregnant KT recipients and for the first time long-
term (up to 10 y) graft function (SCr) after pregnancy. We 
included new studies since 2010 and studies with nullipa-
rous KT recipient control groups. In addition, systematic 
review was performed to give an overview of predictors 
for adverse long-term graft outcomes after pregnancy.
MATERIALS AND METHODS
Search Strategy and Study Selection
A systematic search of literature was performed in 
Pubmed, Embase, and Cochrane library to identify all 
studies on SCr and GL after pregnancy in KT recipients 
until September 2018 (Appendix 1, SDC, http://links.lww.
com/TP/B836). Two reviewers (A.S. and N.P.) indepen-
dently screened the abstracts of all eligible studies. Studies 
reported in English, focusing on SCr or GL following 
pregnancy in KT recipients were eligible. Furthermore, we 
conducted snowballing strategy to include eligible reports. 
Case studies, reviews, and studies that reported <6 months 
postpregnancy follow-up were excluded.
Data Extraction
Two independent reviewers (A.S. and M.B.) extracted 
data from all eligible studies. The following data were 
extracted from each study: study outcomes on prepreg-
nancy SCr, postpregnancy SCr, and GL or graft survival. 
For all the included studies, data on pre- and postpreg-
nancy SCr were extracted or calculated in mean ± SD (in 
mg/dL). When median with range were reported, the mean 
± SD were calculated by the method of Hozo et al.11 SCr 
levels that were reported in µmol/L were converted into 
mg/dL. If graft survival was reported, this was converted 
to GL. In 11 studies, there were missing or incomplete 
data, this was requested from the authors and in 3 cases we 
gained enough information to include them in our meta-
analysis. Using the observational cohort studies with a con-
trol group, it was examined whether pregnancy affects GL 
or SCr, versus nulliparous KT recipients. In addition, all 
included studies were reviewed for different predictors of 
adverse graft outcomes (eg, hypertension, proteinuria, SCr 
before pregnancy, and transplant to conception interval).
Pooled Estimates
To pool data on GL and postpregnancy SCr, subcatego-
ries were created based on the number of years postpartum. 
Articles on GL were divided into 4 categories based on 
timing since pregnancy: GL within 2 year postpregnancy, 
2–5 year, 5–10 year postpregnancy, and >10 year post-
pregnancy. Data on SCr postpregnancy were divided into 
3 subcategories: within 2 year postpregnancy, 2–5 years, 
and 5–10 years postpregnancy. The difference between 
postpregnancy SCr and prepregnancy SCr (∆ SCr) was cal-
culated. For binary outcomes (GL), pooled estimates and 
95% confidence intervals were calculated using Excel.12 
For continuous outcomes (pre- and postpregnancy SCr), 
pooled estimates and 95% confidence intervals were cal-
culated using mean difference and random effect size, con-
ducted by Review Manager 5.3.13
Quality Assessment and Assessment of  
Publication Bias
Two reviewers (A.S. and M.B.) screened the studies for 
full text and performed a critical appraisal on applicability 
and validity (Appendix 2, SDC, http://links.lww.com/TP/
B836). Every study was scored for design, size, domain, 
determinant, outcome, missing data, lost to follow up, 
standardization of outcome, analysis, confounding factors, 
and the possibility to extract data. To test for publication 
bias, we performed funnel plot analysis for every subtopic 
within GL and SCr.
RESULTS
As a result of the search from 3 electronic databases, 
1416 studies qualified for abstract screening. Among 
these, 43 individual publications were selected for inclu-
sion of which 38 studies reported on GL and 18 articles on 
SCr postpregnancy (Figure 1). One study by Levidiotis14 
divided graft survival in different periods of time that is 
why we could only use the data of the subanalysis of the 
matched cohort. Ten of these were observational cohort 
studies with a control group,3,14-22 Table  1 presents the 
study characteristics and reported graft outcomes for all of 
the included studies.
Pooled Incidence of GL After Pregnancy in KT 
Recipients
A total of 38 studies reported on GL in 2453 recipi-
ents. Median follow-up time was very heterogenic among 
the studies and varied from 6 months until 15 years after 
pregnancy GL occurred in 321 (13%) patients following 
© 2019 Wolters Kluwer  1677van Buren et al
pregnancy. The risk on GL is increasing in time with pooled 
incidences of 9.4%, 9.2%, 22.3%, and 38.5% for <2 year, 
2–5 year, 5–10 year, and >10 years after pregnancy, respec-
tively (Figure 2A–D).
Among the 10 studies with a nulliparous control groups, 
matching criteria differed as shown in Table 2. The median 
follow-up time of these studies was 100 months (range 
45–168) after pregnancy.
Pooled Incidence of SCr After Pregnancy in KT 
Recipients
The postpregnancy data of 18 individual studies on SCr 
within women were pooled in 3 postpartum time intervals. 
Fourteen studies reported on 1-year postpregnancy SCr in 
KT recipients. A pooled increase in SCr is seen of 0.18 mg/
dL, 95% CI [0.05-0.32], P = 0.01 in the group compar-
ing prepregnancy SCr within 2-year postpregnancy SCr. 
(Figure 3A) Four studies reported on SCr 2–5 years fol-
lowing pregnancy, and only 2 studies on long-term (5–10 
y) postpregnancy SCr and no significant differences were 
found when comparing pre- versus postpregnancy SCr 
(Figure 3B and C).
Predictors of Adverse Outcomes on Graft Function 
and Risk of GL
Among the included studies,3,4,16,18,19,22,24,26,31,37,41-43, 
47,48,50,54 different predictors of adverse outcomes on graft 
function were described, including hypertension before 
pregnancy, presence of proteinuria before pregnancy, pre-
eclampsia, SCr before pregnancy, and transplant to con-
ception interval (TCI). An overview of the literature on 
these risk factors is given and described in more detail 
below (Table 3). In addition to these most reported risk 
factors, some incidental risk factors were reported. Type 
of delivery or type of donor was no significant risk factor 
for GL.23 High panel reactive antibody (PRA) levels and 
donor-specific anti-HLA antibodies (DSA) have a high risk 
of antibody-mediated rejection (AMR) and have more pre-
eclampsia.25 The type of immunosuppressive regime had 
no effect on graft survival.38,48
Preconceptional Hypertension as a Risk Factor for 
Accelerated GL
Four studies reported an effect of hypertension, before, 
or at the beginning of pregnancy, in relation to long-term 
graft function.4,23,42,48 Hypertension was defined as blood-
pressure >140/90 mm Hg. These 4 authors concluded that 
(drug treated) hypertension before pregnancy is associ-
ated with worse graft function or is a risk factor for graft 
function decline and/or chronic rejection. In one of these 
studies, postpregnancy graft function (SCr) was compared 
between patients with hypertension before pregnancy 
(n = 5) and no hypertension before pregnancy (n = 15). 
The SCr was significantly worse (P = 0.03) in patients with 
hypertension before pregnancy.23 Another study showed 
that hypertensive patients (n = 28) compared to normoten-
sive patients (n = 23) had worse graft function (SCr) before 
pregnancy (1.39 mg/dL versus 1.10 mg/dL), P ≤ 0.01.47 
Two recent studies of which one was a matched cohort 
study did not see a relation between graft failure and 
chronic hypertension.22
Preconceptional Proteinuria and Preconceptional SCr 
as Risk Factors for Accelerated GL
Proteinuria before or during pregnancy, especially pro-
teinuria of >1 g/day, is associated with worse graft sur-
vival.48,55 Two studies, which compared high levels of 
FIGURE 1. Study selection for studies reporting postpregnancy graft function and/or postpregnancy graft loss.
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proteinuria (>0.3 or 0.5 g/d), found no deleterious effect 
on SCr or GL.50,54
Ten different studies analyzed the influence of prepreg-
nancy SCr on graft outcomes (SCr postpregnancy and 
GL or graft survival). Multiple different cut-off values 
were described among these studies, ranging from SCr 
> 1.47 mg/dL to 2.26 mg/dL and >1.0 mg/dL to 2.1 mg/
dL.18,24,26,42,43,47,48,50,54 Ten studies found a negative effect 
on graft function in patients with high SCr before preg-
nancy. Eight of them used SCr > 1.47 mg/dL as cut off 
point,18,24,26,31,43,47,48,50 1 study defined worse graft func-
tion as >1.24 mg/dL, 2 of them used no cutoff point where 
one described a negative effect of worse graft function 
(OR 1.71, 95% CI [1.15-3.45], P = 0.04)22 and one found 
no relationship between prepregnancy SCr and GL (OR 
–0.11, 95% CI [–0.44 to 0.23], P = 0.52). Two other stud-
ies used cut off points <2.26 mg/dL and <1.3 mg/dL also 
found no negative effect on postpregnancy graft function 
in women with high SCr before pregnancy41,54 (Table 3).
Pre-eclampsia as a Risk Factor for Accelerated GL
The development of pre-eclampsia during pregnancy 
was mentioned by 1 study as factor for graft dysfunction 
during pregnancy.24 Pre-eclampsia was defined as hyper-
tension and proteinuria >0.30 g/24 h. One study showed 
that pre-eclampsia was a “borderline” risk factor for GL 
(OR 1.09; 95% CI [0.92-1.34], P = 0.09).22 The latest 
matched cohort study did not see a relation between pre-
eclampsia and GL.51
Transplant to Conception Interval as a Risk Factor for 
Accelerated GL
The relationship between transplant to conception inter-
val (TCI) and graft function is reported by 5 individual 
studies, which report on different outcomes of TCI (in gen-
eral, TCI < 1 y, TCI < 2 y, TCI > 5 y).3,16,19,26,37 Stoumpos 
et al found no negative relationship between graft func-
tion and TCI.3 One study found more GL in patients with 
TCI < 1 year,26 whereas another study found no significant 
impact on graft outcome.19 In another study, there was no 
adversely effect on graft survival in patients with TCI < 2 
year, compared to other subgroups.16 A TCI of >5 years 
has acceptable outcomes on postpregnancy graft func-
tion and rejection during pregnancy and up to 3 months 
postpartum.37
Assessment of Quality and Publication Bias
We assessed study quality with the use of critical 
appraisal on applicability and validity (Appendix 2, SDC, 
http://links.lww.com/TP/B836). Seventeen studies had a 
sample size of <20 women. Missing data were not well 
described in 21 of the studies. Ten studies did not describe 
their statistical analysis precisely. In 6 studies, possible 
confounding factors were not mentioned in the article. 
Publication bias for studies on GL is unlikely as GL fun-
nel-plot shows symmetry (Appendix 3, SDC, http://links.
lww.com/TP/B836). There is a funnel-plot asymmetry in 
the subgroup of ∆ SCr <2 years after pregnancy indicat-
ing publication bias toward the publication of small stud-
ies with positive ∆ SCr values (Appendix 4A, SDC, http://
links.lww.com/TP/B836).T
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DISCUSSION
In this meta-analysis and systematic review, we aimed 
to investigate the effect of pregnancy on long-term graft 
survival and function as guidance for preconceptional 
counseling using data derived from 42 studies. This meta-
analysis gives an update on GL after pregnancy after KT. 
It includes cohort studies with nulliparous control groups 
and pooled data on graft function after pregnancy after 
KT. We are the first to analyze pooled data on long-term 
SCr after pregnancy in KT recipients. GL and SCr after 
pregnancy in KT recipients are reassuring with no differ-
ence in GL when compared to nulliparous KT recipients 
and stable SCr up to 10 years postpartum. We only found 
a slight significant rise in SCr in the period within 2 years 
after delivery of 0.18 mg/dL of which it can be discussed 
if such a small increase is clinically relevant, especially 
since ∆ SCr was not increased at later time points after 
pregnancy.
The present meta-analysis added >500 women from 23 
additional studies to the literature since the last meta-anal-
ysis from 2011 on the subject.1 We report slightly higher 
outcomes on GL within 2 years (9.4% versus 8%) and 
higher numbers of GL of 22.3% versus 19% after 5–10 
years postpregnancy, this was mainly caused by the TPR 
report.2 Desphande reported 12.5-year postpregnancy GL 
of 11%, based on one study of Gorgulu.39 We could not 
include this study in our meta-analysis because they only 
reported on GL after KT and not on GL after pregnancy. 
Our outcome of GL of 38.5% >10-year postpartum is 
based on a pooled incidence of 5 new studies.14,20-22,43
We added 10 studies that compared the result of GL 
after KT with a nulliparous KT control group. The absence 
of a difference in GL between parous and nulliparous is 
reassuring. We ascertained that the control groups used 
were heterogenic among the studies: almost all studies 
were age and SCr before conception matched. The ques-
tion remains whether the used control groups are really 
comparable because the reason they did not conceive 
might be the result of other underlying conditions, which 
also can influence SCr and GL.
This study provides us insight into incidence of GL 
per years postpartum. It would have been informative 
to perform the same analyses per years posttransplant. 
Unfortunately, posttransplant years were rarely reported, 
which restricted us from performing this analysis. 
Therefore, it is hard to compare our results with the GL 
numbers from the registries. When comparing GL results 
after pregnancy to the age group of 16–34 years (men and 
women) of the Eurotransplant region, the number of GL 
after pregnancy are lower than the number of GL after 
KT in the general KT population. Ten years GL after KT 
(living and postmortal donors) is 46% and 15 years GL 
is 60% for this age group in the Eurotransplant region.56 
This finding of relatively good graft survival in women 
with pregnancy after KT is reassuring. Although the argu-
ment that KT recipients with worse renal and physical 
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FIGURE 2. A–D, Pooled incidence of postpregnancy graft loss. A, Graft loss within 2 y postpregnancy: 9.4%, n = 1347 (range 10–
1100), total graft loss n = 126 (range 0–111). B, Graft loss 2–5 y postpregnancy: 9.2%, n = 600 (range 8–139), total graft loss n = 55 
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condition are less likely to get pregnant also counts for this 
comparison.
In addition to previous meta-analysis,1 we examined 
long-term graft function after pregnancy in KT recipients. 
A small significant rise in SCr within 2 years after deliv-
ery as described in 87 KT recipients derived from 3 stud-
ies.30,43,44 Possibly, this might be caused by physiological 
changes after pregnancy or restart of medication such as 
ACE inhibitors. On the contrary, this could be the result 
of high rate of risk factors in the study population (65.9% 
hypertension, 36.5% SCr >1.5 mg/dL before pregnancy43), 
which makes these women more prone for deterioration 
of graft function or even GL. Most importantly, we do not 
find an increase in SCr during the period 5 years after preg-
nancy. However, women with a malfunctioning graft or 
lost to follow-up are not present in subgroups longer time 
after pregnancy possibly inducing bias. This is in line with 
the recent systematic review on the effect of pregnancy in 
chronic kidney disease, which reported no shift in CKD 
stage after pregnancy.57
Risk factors for GL after pregnancy in KT were hyper-
tension, proteinuria, transplant to conception/delivery 
interval, and preconception graft function. However, only 
a few of the studies reporting on these risk factors per-
formed a multivariate analysis, influenced by power. It is 
difficult to establish cause-relationship effects of risk fac-
tors. These risk factors are mentioned in the European and 
American guidelines, aiming at improving outcome in KT 
recipients.9,10 The TCI is a point of discussion as it was 
stated by the European guidelines for 2 years after KT. 
The American guidelines changed their advice to postpone 
pregnancy at least until 1 year after pregnancy. Studies such 
as Fischer and Pour Reza Gholi showed reassuring results 
of pregnancies after 1 year after pregnancy.16,19 Pregnancy 
within 1 year after KT is associated with an increased risk 
on GL, which Rose et al showed in their recent study.58 
Data on the association of pre-eclampsia with GL show 
confliction results.23,24,51
The strength of our meta-analysis is that we pooled data 
on GL including studies with a nulliparous control group 
and for the first time examined pooled incidences of graft 
function after pregnancy. One of the limitations of this 
study is that the quality of some studies was poor with 
small sample size. The funnel plot analysis in the subgroup 
of ∆ SCr 24 months after pregnancy showed an asym-
metry, possibly publication bias is present (Appendix 4A, 
SDC, http://links.lww.com/TP/B836). In addition, this is an 
unadjusted meta-analysis in which we could not account 
for factors such as differences in healthcare systems or 
socio-economic status or difference in SCr measurements 
because of lack of such information.
Unfortunately, we were not able to perform a meta-
analysis on estimated glomerular filtration rate (eGFR). 
Most studies only report SCr without age, calculation 
of eGFR was not possible.59 We assumed that precon-
ceptional creatinine was really preconceptional as it was 
A
B
C
FIGURE 3. A–C, Pooled difference (mean difference [95% CI] in prepregnancy SCr and postpregnancy SCR (∆ SCr pre- and 
postpregnancy). A, Delta SCr within 2 y postpregnancy: SCr 0.18 mg/dL [0.05, 0.32], P = 0.007, n = 441. B, ∆ SCr 2–5 y postpregnancy: 
SCr 0.17 mg/dL [–0.03, 0.37], P = 0.09, n = 175. C, ∆ SCr 5–10 y postpregnancy: SCr 0.10 mg/dL [–0.12, 0.32], P = 0.38, n = 101. CI, 
confidence interval; SCr, serum creatinine; SD, standard deviation.
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stated in the text. It could be possible that the precon-
ceptional SCr that was used for the included studies were 
not completely preconceptional and that the SCr was 
already physiologically increased. Ultimately, evalua-
tion of individual slope of eGFR pre- and postpregnancy 
would be performed by means of a multilevel analysis 
to answer the question whether pregnancy has effect on 
longer-term GFR. Additionally, it would be possible to 
identify the most important predictors for worse graft 
outcomes after pregnancy after KT in relation to eGFR 
slope change.
In conclusion, this systematic review and meta-analysis 
showed a possible association with short-term SCr decline 
postpartum, but no association at longer periods of time 
after delivery. The incidence of GL up to 10 years post-
pregnancy is limited but data analyzed show reassuring 
data on GL with pregnancy after KT compared to nullipa-
rous controls and age-matched and SCr-matched controls. 
This should be taken into consideration during preconcep-
tional counseling. Based on the risk factors for GL, it could 
be concluded that if prepregnancy KT function is good, 
it remains good after pregnancy. Systematic review of the 
literature showed that mainly prepregnancy proteinuria, 
hypertension, and high SCr are risk factors for GL.
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